Gilead (GILD) announced that Dietmar Berger will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead’s senior leadership team. Berger succeeds Merdad Parsey. Most recently, Berger was the Chief Medical Officer and Global Head of Development at Sanofi, where he led development science, strategy and operations across the company’s therapeutic areas of focus. Prior to Sanofi, Berger served in senior development roles at Atara, Genentech, Bayer and Amgen.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- eBay downgraded, GM upgraded: Wall Street’s top analyst calls
- Gilead reinstated with a Buy at BofA
- Gilead’s Kite announces results from 5-year follow-up study of Yescarta in NHL
- Gilead price target raised to $115 from $105 at Oppenheimer
- Arcellx, Gilead announce new data from iMMagine-1 study of anitocabtagene autole